Drug Profile
NNC 260161
Latest Information Update: 14 Apr 1998
Price :
$50
*
At a glance
- Originator Novo Nordisk
- Class Hormones; Oligopeptides; Small molecules
- Mechanism of Action Growth hormone releasing factor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Somatotropin deficiency
Most Recent Events
- 14 Apr 1998 Discontinued-I for Somatotropin deficiency in Denmark (Unknown route)
- 27 May 1997 Phase-I clinical trials for Somatotropin deficiency in Denmark (Unknown route)